Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 14, 2019 ) North America Conjugate Vaccine Market: Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%. Scheduled conjugated vaccinations, have eradicated health disparities and consequently led to lower rate of disease incidence.
Download Free Report Sample (PDF) Here:https://www.researchreporthub.com/report/north-america-conjugate-vaccine-market/11305/#requestforsample
Market Segmentation:
o Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics in North America was in the case of DTP vaccines. o Based on end user, the market is segmented into pediatric and adult. o Based on countries, the market is divided into U.S. and Canada.
Key growth factors:
North America is projected to be one of the most significant markets for conjugate vaccines during the forecast period, due to a rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Increased diagnosis and treatment are considered to fuel the North American conjugate vaccine market. Recommended vaccines and dosages are updated on a regular basis to comply with prevalent serogroups of infectious agents. For example, the CDC has its own immunization schedule for US citizens. This has increased the effectiveness of administered vaccines, which thereby increases the demand for the product, leading to increase in market sales.
Threats and key players:
o The North America conjugate vaccine market is expected to grow positively. But since it is a saturated market, the scope for significant growth is limited. In North America, the population above 65 years of age has decreased from 53,000,000 in 2014 to 51,900,000 in 2016. So, the demand for adult vaccines has also reduced. The overall penetration rate for the adult segment is lower than that of the pediatric segment. o Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
Get Discount & Customization of this Report Here:https://www.researchreporthub.com/report/north-america-conjugate-vaccine-market/11305/
Table Of Content
Chapter 1: Executive summary 1.1 Market scope and segmentation 1.2 Key questions answered in this study 1.3 Executive summary - I 1.4 Executive summary - II
Chapter 2: Market overview 2.1. Market definitions 2.2. North America market overview by revenue - North America historical (2015-2017) market revenue (USD Bn) - North America forecasted (2018-2023) market revenue (USD Bn) - Country-wise market (2018-2023) revenue (USD Bn) 2.3. North America market overview by volume - North America historical (2015-2017) market volume (Million units) - North America forecasted (2018-2023) market volume (Million units) - Country-wise (2018-2023) market volume (Million units) 2.4. North America market drivers and challenges 2.4.1. North America market drivers 2.4.2. North America market challenges 2.5. North America market trends 2.6. Value chain 2.7.1. Country-specific market overview U.S. - Observation - Key competitors 2.7.1(A) Country-specific market overview U.S. by revenue and by volume - U.S. historical (2015-2017) market revenue (USD Bn) - U.S. forecasted (2018-2023) market revenue (USD Bn) - U.S. historical (2015-2017) market volume (Million units) - U.S. forecasted (2018-2023) market volume (Million units) 2.7.2. Country-specific market overview Canada - Observation - Key competitors 2.7.2(A) Country-specific market overview Canada by revenue and by volume - Canada historical (2015-2017) market revenue (USD Bn) - Canada forecasted (2018-2023) market revenue (USD Bn) - Canada historical (2015-2017) market volume (Million units) - Canada forecasted (2018-2023) market volume (Million units)
Chapter 3: North America major segment overview - by disease indication 3.1. Disease indication: Pneumococcal, Hib - by revenue, by volume, CAGR - Overview - by disease indication - Market share (2015, 2018 & 2023): Pneumococcal North America (USD Bn, Million units) - Market share (2015, 2018 & 2023): Hib North America (USD Bn, Million units) 3.2. Disease indication: DTP, Meningococcal - by revenue, by volume, CAGR - Overview - by disease indication - Market share (2015, 2018 & 2023): DTP North America (USD Bn, Million units) - Market share (2015, 2018 & 2023): Meningococcal North America (USD Bn, Million units)
......
Get Complete TOC with Figures and Tables Here:https://www.researchreporthub.com/report/north-america-conjugate-vaccine-market/11305/#toc
Research Report Hub Research Report Hub offers wide-ranging collection of market research reports under virtually every market verticals and sub-categories from different publishers across the globe. We offer reliable market intelligence reports and report customization services to better understand current and projected market scenarios. It also gives a clearer depiction of industries and facilitates to simply perceive competitor activity in the respective industry. Our services are also geared towards helping organizations procure market reports at the finest price. About US
Research Report Hub Sector 04, Plot 101, Sant Nagar, Moshi PCNDTA, Pune, 412105 Maharashtra, India
Web:www.researchreporthub.com Find us on: <||>rnhttps://www.facebook.com/reasearchreporthub/ <||>rnhttps://twitter.com/hub_report <||>rnhttps://www.linkedin.com/company/research-report-hub/
Research Report Hub
Prakriti Mathur
+918448444687
sales@researchreporthub.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|